Cantargia
Patrik Renblad has extensive experience in financial leadership within the pharmaceutical and biotech sectors. Currently serving as Chief Financial Officer at Cantargia AB since June 2023, Patrik previously held the same title at SynAct Pharma AB, where responsibilities included leading the finance function for a biotech firm focused on inflammatory conditions. Patrik's career at LEO Pharma spanned several roles, including Director of R&D Business Finance and Finance and Patient Access Director in China, leading finance operations and strategic initiatives. Earlier experience includes various finance and consulting positions at AstraZeneca R&D, Assistera, and AdraSoft AB. Patrik holds a Master’s degree in Business Administration and Economics from Lund University.
This person is not in any offices
Cantargia
1 followers
Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar.